Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

03.11.2026

Aspen Sells European Ovestin Rights, Retains Supply Role

Aspen Ovestin sale will raise €197m while preserving a manufacturing role. Explore the deal terms and implications for its portfolio strategy.
Aspen Ovestin sale transfers European commercial rights to Ennogen while retaining manufacturing and supply
Image Supplied

The Aspen Ovestin sale will transfer European commercial rights to Ennogen Healthcare International for €197 million, while Aspen retains manufacturing and supply contracts.

Wholly owned subsidiary Aspen Global will sell the commercialisation rights and associated intellectual property. The price equates to approximately R3.7 billion, with related inventory adding an estimated €4 million.

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

More from Health Matters

03.11.2026

KeyHealth Ordered to Fully Fund Teenager’s Rare-Disease Treatment

A KeyHealth PMB ruling orders full funding for treatment for a teenager’s rare blood disorder. The scheme plans to challenge the decision.

02.11.2026

Healthcare Consensus Initiative Seeks Common Ground

A healthcare consensus initiative seeks agreement on universal coverage and action on failing services. Read about its priorities.

02.11.2026

Dis-Chem digital platform targets growth

Explore the Dis-Chem digital platform and see how it connects prescriptions and shopping in a seamless online experience.